Teva Recalls One Lot of Thrombocytopenia Treatment
May 23, 2022FDA Approves Novel Treatment for Plaque Psoriasis
May 24, 2022May 24, 2022 – The U.S. FDA has approved Tyvaso DPITM (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
- Tyvaso DPI is the only FDA-approved dry powder inhaler for PAH and PH-ILD. It is a new formulation of treprostinil, the active pharmaceutical ingredient of Tyvaso® inhaled solution. Both products are made by United Therapeutics.
- Recommended dosing for Tyvaso DPI is one 16mcg cartridge per treatment session to start, titrated up to a target maintenance dose of 48mcg to 64mcg per session. The recommended dosing frequency is four separate treatment sessions each day, set approximately four hours apart, during waking hours.
- The medication has launched with a wholesale acquisition cost (WAC) of $20,906.09 for a 28-day supply of the maintenance dose.